Adlai Nortye Ltd. (ANL)
| Market Cap | 466.00M |
| Revenue (ttm) | 5.00M |
| Net Income (ttm) | -35.53M |
| Shares Out | 40.00M |
| EPS (ttm) | -1.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 943,105 |
| Open | 12.87 |
| Previous Close | 13.25 |
| Day's Range | 11.31 - 13.10 |
| 52-Week Range | 0.88 - 17.25 |
| Beta | -0.71 |
| Analysts | Strong Buy |
| Price Target | 20.00 (+71.67%) |
| Earnings Date | Apr 10, 2026 |
About ANL
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and develops pharmaceutical products in the United States and internationally. Its lead product is AN8025, a tri-functional fusion protein of αPD-L1 x CD86 variant x LAG3 variant, a T-cell and antigen-presenting cell modulator, which is in phase 1a clinical trials for the treatment of tumor. The company also developing AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers include pancrea... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ANL stock is "Strong Buy" and the 12-month stock price target is $20.0.
News
Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
SINGAPORE and NORTH BRUNSWICK, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the develop...
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company foc...
Adlai Nortye Announces $140.0 Million Private Placement Equity Financing
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd.
Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company foc...
Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company foc...
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focu...
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focu...
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company fo...
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company foc...
Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a global clinical-stage biotechnology comp...
Adlai Nortye Ltd. Announces Closing of Initial Public Offering
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company foc...
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company fo...
Cancer treatment company Adlai Nortye sets terms in IPO
Adlai Nortye Ltd. said late Thursday it plans to offer three million American depositary shares at an estimated price of $22 to $26 a share in its initial public offering on the Nasdaq under the symbo...